[go: up one dir, main page]

ES2070172T3 - Procedimiento para producir proteinas mediante adn recombinante. - Google Patents

Procedimiento para producir proteinas mediante adn recombinante.

Info

Publication number
ES2070172T3
ES2070172T3 ES89303767T ES89303767T ES2070172T3 ES 2070172 T3 ES2070172 T3 ES 2070172T3 ES 89303767 T ES89303767 T ES 89303767T ES 89303767 T ES89303767 T ES 89303767T ES 2070172 T3 ES2070172 T3 ES 2070172T3
Authority
ES
Spain
Prior art keywords
procedure
recombinant dna
producing proteins
host cell
synthesised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89303767T
Other languages
English (en)
Inventor
Raymond John Owens
Gregory Paul Winter
Lutz Riechmann
Geoffrey Thomas Yarranton
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2070172(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888809050A external-priority patent/GB8809050D0/en
Priority claimed from GB888811342A external-priority patent/GB8811342D0/en
Priority claimed from GB888820284A external-priority patent/GB8820284D0/en
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ES2070172T3 publication Critical patent/ES2070172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION PREVEE UN METODO PARA LA PRODUCCION DE FRAGMENTOS FV QUE COMPRENDE: TRANSFORMACION DE UNA CELULA EUCARIOTICA CON UN VECTOR DE EXPRESION AUCARIOTICO QUE COMPRENDE UN OPERON CON UNA SECUENCIA DE DNA QUE CODIFICA PARA UN DOMINIO VARIABLE SOLAMENTE DE UN ANTICUERPO DE CADENA LIGERA O PESADA. CULTIVO DE LA CELULA HUESPED TRANSFORMADA BAJO CONDICIONES QUE CAUSAN LA PROTEINA CODIFICADA POR LA SECUENCIA DE DNA QUE SE VA A SINTETIZAR, Y RECOLECCION DE LA PROTEINA SINTETIZADA. FIG.1.
ES89303767T 1988-04-16 1989-04-17 Procedimiento para producir proteinas mediante adn recombinante. Expired - Lifetime ES2070172T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888809050A GB8809050D0 (en) 1988-04-16 1988-04-16 Expression of antibody heavy & light chain variable domains as an fv-fragment
GB888811342A GB8811342D0 (en) 1988-05-13 1988-05-13 Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
GB888820284A GB8820284D0 (en) 1988-08-26 1988-08-26 Method for producing recombinant dna proteins

Publications (1)

Publication Number Publication Date
ES2070172T3 true ES2070172T3 (es) 1995-06-01

Family

ID=27263864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89303767T Expired - Lifetime ES2070172T3 (es) 1988-04-16 1989-04-17 Procedimiento para producir proteinas mediante adn recombinante.

Country Status (9)

Country Link
EP (1) EP0338745B1 (es)
JP (2) JP3105898B2 (es)
AT (1) ATE119198T1 (es)
AU (1) AU627183B2 (es)
CA (1) CA1341411C (es)
DE (1) DE68921364T2 (es)
ES (1) ES2070172T3 (es)
GR (1) GR3015248T3 (es)
WO (1) WO1989009825A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
CA2234666A1 (en) * 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
WO1997015601A1 (en) * 1995-10-20 1997-05-01 Novartis Ag Process for the preparation of a single chain fv antibody fragment
ATE248192T1 (de) 1996-06-07 2003-09-15 Neorx Corp HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
JP2000164361A (ja) 1998-11-25 2000-06-16 Tdk Corp 有機ｅｌ素子
IL146480A0 (en) 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
JP4819285B2 (ja) 2000-05-16 2011-11-24 トーマス・ジェファーソン・ユニバーシティー 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法
SI3031910T1 (en) 2002-02-21 2018-05-31 Institute Of Virology Slovak Academy Of Sciences MN / CA IX-SPECIFIC MONOCLONIC PROTECTOR GENERATED FROM MN / CA- DEFROSTABLE MICE AND METHOD OF APPLICATION
MXPA05000832A (es) 2002-07-19 2005-10-19 Beth Israel Hospital Metodos de diagnosticar y tratar pre-eclampsia o eclampsia.
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
JP5270161B2 (ja) 2004-09-24 2013-08-21 ベス イスラエル デアコネス メディカル センター 妊娠合併症を診断および処置する方法
CN102397542B (zh) 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
EP1909819A4 (en) 2005-06-17 2010-02-17 Imclone Llc RECEPTOR ANTAGONISTS FOR THE TREATMENT OF METASTATIC BONE CANCER
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN101970500B (zh) 2008-03-12 2013-08-14 伊姆克罗尼责任有限公司 抗tyrp1抗体
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US9163086B2 (en) 2009-08-18 2015-10-20 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020242989A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382317D1 (de) * 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3785186T2 (de) * 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.

Also Published As

Publication number Publication date
JPH11225758A (ja) 1999-08-24
AU3536489A (en) 1989-11-03
DE68921364T2 (de) 1995-06-29
CA1341411C (en) 2002-12-17
JPH03500005A (ja) 1991-01-10
ATE119198T1 (de) 1995-03-15
EP0338745A1 (en) 1989-10-25
WO1989009825A1 (en) 1989-10-19
AU627183B2 (en) 1992-08-20
GR3015248T3 (en) 1995-06-30
EP0338745B1 (en) 1995-03-01
JP3105898B2 (ja) 2000-11-06
DE68921364D1 (de) 1995-04-06

Similar Documents

Publication Publication Date Title
ES2070172T3 (es) Procedimiento para producir proteinas mediante adn recombinante.
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
GB2137631B (en) Multichain polypeptides and processes for their production
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
PT990044E (pt) Metodo para evolucao molecular in vitro da funcao de proteinas
ATE365800T1 (de) Therapeutische verwendungen von il-17 homologe polypeptide
DE3587524D1 (de) Herstellung von chimaeren antikoerpern.
EA200000216A1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
DK1246917T3 (da) Humane Stra6-polypeptider
PT1169442E (pt) Polipeptidos segregados e transmembranares e acidos nucleicos que os codificam
DE59308000D1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
DE3854581D1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
WO1996031603A3 (en) Methods and compositions for regulating fadd
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
FI102383B1 (fi) Menetelmä ja plasmidi modifioidun PE40-domeenia sisältävän hybridiproteiinin valmistamiseksi
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
EP0688224A4 (en) MUTANT PROTEIN, METHODS AND MATERIALS USED FOR ITS MANUFACTURE AND USE
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
DE69721629D1 (de) An Nukleinsäure gebundenes Polypeptid, Verfahren zur Herstellung eines an Nukleinsäure gebundenen Polypeptides und Immunoassay, in dem dieses Polypeptid Verwendung findet
DK1233980T3 (da) Nukleinsyremolekyle, omfattende en nukleinsyresekvens, der koder for et hæmocyanin, og mindst en intronsekvens
EA200100440A1 (ru) Ген prv-1 и его применение
PT1217006E (pt) Polipeptidos e acidos nucleicos que os codificam
KR950018455A (ko) 대장균에서 가용성 인간 인터루킨-1베타의 생산 및 정제방법
PT1251173E (pt) Polipeptidos transmembranares e excretados e acidos nucleicos que os codificam

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 338745

Country of ref document: ES